The mesenchymal stem cell market is expected to grow at a pace

Visiongain has released a new report titled Mesenchymal Stem Cells Market 2022-2032. It includes Mesenchymal Stem Cells Market Profiles and Market Segment Forecast by Type {Product (Cells & Cell Lines, Carrier & Reagent Kits, Others), Services}, Market Segment by Source (Bone Marrow, Adipose Tissue , cord blood, fallopian tube, fetal liver, lung, peripheral blood, other sources), market segment by indication (bone and cartilage repair, cardiovascular diseases, cancer, GvHD, inflammatory and immunological diseases, liver diseases, Other Diseases), Market Segment by Application (Disease Modeling, Drugs Discovery and Development, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications) plus COVID-19 Impact Analysis and Recovery Model Analysis (“ V-shaped”, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of major companies, region and countries.

The Mesenchymal Stem Cells Market was valued at USD 2.44 Billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

Growing awareness of the therapeutic potential of mesenchymal stem cells
The mesenchymal stem cell (MSC) market has enormous potential for expansion as it is the most widespread type of stem cell used in regenerative medicine. MSCs are now the most commonly used type of stem cell in clinical trials and the most studied type of stem cell in the scientific literature. CSM-based therapies are also gaining popularity due to the rapidly aging population and increasing prevalence of chronic diseases. Mesenchymal stem cells play an important role in the effective management of disease and research initiatives in specialized areas such as genomic testing and personalized medicine. Due to the growing awareness of the therapeutic potential of stem cells and the scarcity of effective therapeutic treatments for rare diseases, there is an increase in investments leading to the growth of the market, but the significant operational cost associated with the expansion and banking of mesenchymal stem cells is expected to hamper the market growth.

Download exclusive sample report @

How Has COVID-19 Significantly Negatively Impacted the Mesenchymal Stem Cells Market?

The biotechnology industry has seen evolutionary changes with respect to operational management. Typical biopharmaceutical companies manufacturing products for mesenchymal stem cell development have responded better to staff disruptions and evolving challenges due to COVID-19.

There was an impact on research and development activities and clinical trials as there were interruptions in the recruitment of new patients for the active clinical trial. However, the company has been focused on inventing new therapies for the treatment of COVID-19 disease. In recent years, MSCs have established themselves as an effective technique for treating lung diseases, including COVID-19. MSC-derived stem cell therapies have shown the potential for the treatment of Covid 19 disease. As a result, an increase in the number of clinical trials using MSCs has been observed. Countries like the US, UK, Belgium, France, Spain and Mexico are conducting clinical trials with mesenchymal stem cells for use in the treatment of COVID-19.

How will this report help you?

Visiongain’s 281-page report provides 117 charts and 184 charts/graphs. Our new study is suitable for anyone requiring in-depth business analytics for the Mesenchymal Stem Cells Market along with detailed analysis of market segments. Our new study will help you assess the global and regional market overall Mesenchymal Stem Cells Market. Obtain financial analysis of the overall market and different segments including type, source, indication, application and company size and capture higher market share. We believe there are strong opportunities in this rapidly growing mesenchymal stem cell market. Find out how to use the existing and upcoming opportunities in this market to generate revenue in the near future. Moreover, the report will help you improve your strategic decision-making, enabling you to set growth strategies, strengthen analysis of other market players and maximize business productivity.

What are the current market drivers?

MSC in the development of modified tissues and organs
hMSCs have been considered as one of the main biological manufacturing materials for decades, as they have been shown to be safe and effective in the treatment of various injuries and diseases such as bone or cartilage regeneration, strokes and cancer. Bioprinting is a rapidly expanding area of ​​tissue engineering with great promise for product customization and addressing the global shortage of tissues and organs, with a forecasted global market of US$1.82 billion. by 2022. hMSCs have also been shown to be able to be guided to hepatocytes. differentiation thus indicating a huge demand for hMSCs as organ tissue engineering develops. The requirement of hMSC in engineered tissue and organ applications depends, of course, on the cell generation, differentiation and maturation technologies for the parenchymal cells necessary for the functioning of the organs and therefore it is expected that that increased availability of hMSC sources as a result of manufacturing technological advancements will pave the way for rapid improvement and growth in the mesenchymal stem cell market.

Focus on regenerative medicine therapies
MSCs are a good source of cells for tissue regeneration due to the following characteristics. MSCs can originate from a variety of tissues, including the umbilical cord, fetal liver, bone marrow, and synovium. MSCs have the ability to grow into virtually any terminal lineage cell, allowing them to seed specific scaffolds. MSCs are potential immunotolerant agents as they have characteristics such as anti-inflammatory, immunoregulatory and immunosuppressive. Several clinical articles confirm the potential efficacy of cell therapy based on MSCs; although its effectiveness is still limited, the results are encouraging.

MSCs have been studied and widely used in regenerative medicine. MSCs have moved closer to therapeutic applications for disease treatment and tissue repair in recent years due to improvements in extraction, culturing, and differentiation procedures. Therefore, future research on better biomaterials and effective inducing factors will help MSCs advance in their regenerative medicine applications.

Get a detailed table of contents @

Where are the market opportunities?

MSC therapy to treat multiple sclerosis
The therapeutic application of MSCs in the treatment of multiple sclerosis has been shown to offer enormous potential by improving clinical symptoms, thereby stabilizing disease progression. MSCs have properties such as immunomodulation, tissue protection and repair promotion have proven MSCs to be an attractive therapeutic option in the treatment of multiple sclerosis as well as other conditions such as inflammation and tissue damage.

When given, MSCs fight inflammation in the body and regulate the immune system, which will further prevent the breakdown of myelin. Clinical trials demonstrating the application of MSCs in patients with multiple sclerosis have shown increased energy levels, improved flexibility, strength and mobility. It has also been observed that if MSCs are administered intravenously, they may have the ability to arrest disease progression for an extended period of time.

MSCs offer intrinsic advantages over hematopoietic stem cells, that MSCs can differentiate into a cell type, release immunoregulatory molecules, and promote the release of exosomes and growth factors

Competitive landscape
Major players operating in the mesenchymal stem cell market are Thermo Fischer Scientific Inc., Merck KGaA (Millipore Sigma), STEMCELL Technologoes Inc., Cytori Therapeutics Inc. (Plus Therapeutics Inc.), Cyagen Biosciences, PromoCell GmbH, Celprogen Inc. Stemedica Cell Technologies Inc., Cell Application Inc., Lonza, Celltex Therapeutics Corporation. These major players operating in this market have adopted various strategies including mergers and acquisitions, R&D investments, collaborations, partnerships, regional business expansion and new product launches.


  • In August 2022, to meet the growing demand for cell culture media used worldwide for the development and manufacturing of new biologics and vaccines, Thermo Fisher Scientific upgraded its dry powder media manufacturing facility in Grand Island, New York.
  • In March 2022, a new large-volume electroporation technology was unveiled by Thermo Fisher Scientific, making it easier for cell therapy inventors to move from clinical development to commercial manufacturing. Without the use of conventional viral vectors, the Gibco CTS Xenon Electroporation System facilitates genetic modification through the use of a closed system
  • In March 2019, Celltex Therapeutics entered into an agreement with the Research Products Development Company (RPDC) of Saudi Arabia to help promote and commercialize Celltex’s proprietary stem cell technology.

Avoid missing out by staying informed – order our report now.

To find more Visiongain research reports on the Pharma sector, click on the following links:

Do you have any custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? Contact us today, we can discuss your needs and see how we can help you: [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market intelligence providers, the company publishes hundreds of market research reports which he adds to his vast portfolio every year. These reports offer in-depth analysis of 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with many synergies. These markets include automotive, aviation, chemical, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmacy and utilities. Our customized and syndicated market research reports offer tailored market intelligence tailored to your unique business needs.

Developer Visavadia
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
E-mail: [email protected]

Comments are closed.